吡美莫司乳膏对阴囊湿疹患者复发率及临床疗效的影响

目的观察吡美莫司乳膏对阴囊湿疹患者复发率与有效率的影响。方法回顾性观察2017年5月～2019年5月我院收治90例阴囊湿疹患者的临床资料,根据治疗方案的不同分为对照组(地塞米松软膏治疗,45例)与观察组(吡美莫司乳膏治疗,45例)。每组早晚各外用1次,连续治疗4周,对比观察两组患者复发与治疗情况。结果观察组的治疗有效率高于对照组,差异有统计学意义(P 0.05);观察组的复发率低于对照组,差异有统计学意义(P 0.05)。结论吡美莫司乳膏治疗阴囊湿疹患者可降低复发率,提高有效率,具有较好的临床治疗效果,值得临床广泛推广应用。     

吡美莫司乳膏治疗线状苔藓疗效观察

目的观察吡美莫司乳膏治疗线状苔藓的临床疗效。方法 92例线状苔藓患者根据就诊序号随机分为2组,治疗组46例给予外用吡美莫司乳膏,对照组46例给予外用卤米松乳膏,均2次/d,观察治疗前和治疗第2,4,8周的临床疗效和不良反应。结果治疗前及治疗后两组患者的评分差异均无统计学意义(P0.05);治疗8周后两组总有效率差异无统计学意义(χ~2=0.27,P0.05)。结论吡美莫司乳膏治疗线状苔藓临床疗效明显,且不良反应少。     

308nm准分子光联合吡美莫司乳膏治疗白癜风疗效观察

目的：评价308 nm准分子光联合吡美莫司乳膏治疗白癜风的疗效和安全性.方法：将150例白癜风患者随机分为3组.治疗组50例,采用308 nm准分子光联合1%吡美莫司乳膏治疗.对照1组50例,采用NB-UVB联合1%吡美莫司乳膏治疗.对照2组50例,单纯外用1%吡美莫司乳膏治疗.3组均连续治疗12～24周,进行临床疗效和不良反应评价.结果：治疗组有效率为92.0%,对照1组为74.0%,对照2组为50.0%.3组患者均未出现严重不良反应.结论：308 nm准分子光联合吡美莫司乳膏治疗白癜风疗效确切,安全性好.     

1%吡美莫司乳膏联合甲氧沙林治疗白癜风疗效观察

目的观察1%吡美莫司乳膏联合甲氧沙林片治疗白癜风的疗效。方法根据随机数字表法将符合入选标准的90例患者分成两组,各45例,对照组口服甲氧沙林片0.3~0.6mg/(kg.d),每3天1次,服药1.5~2.0h后阳光照射,强度以发生轻度红斑为宜,治疗期间戴墨镜保护眼睛;试验组同时加用1%吡美莫司乳膏,两组均连续治疗3个月。结果试验组和对照组有效率分别为75.6%和37.8%,差异有显著性(P<0.01)。试验组3例皮肤有烧灼感。结论1%吡美莫司乳膏联合甲氧沙林片治疗白癜风临床疗效好。     

1%吡美莫司乳膏治疗面部激素依赖性皮炎疗效观察

目的观察1%吡美莫司乳膏治疗面部激素依赖性皮炎的临床疗效和安全性。方法采用随机、自身对照、开放式的临床试验设计。48例面部激素依赖性皮炎患者,1%吡美莫司乳膏2次/d外涂靶皮损,观察皮损和自觉症状变化并与治疗前对比。结果治疗6周后,48例患者有效率为100%。8例患者出现刺痛和烧灼感,未中断治疗,总体耐受性好,无特殊不良反应。结论 1%吡美莫司乳膏治疗面部激素依赖性皮炎,疗效明显,不良反应少,患者依从性高。     

面部经换肤和嫩肤术后皮肤敏感的临床治疗

目的探讨嫩肤、换肤术后的面部敏感皮肤的治疗。方法将200例患者随机分为4组:A组:仅外用保湿剂,2次/d;B组:口服氯雷他定片10mg/d,外用保湿剂2次/d;C组:口服氯雷他定片10mg/d,外用吡美莫司乳膏1次/d及保湿剂2次/d;D组:口服氯雷他定片10mg/d,用马齿苋煎液局部冷敷15min,2次/d,后外用吡美莫司乳膏1次/d及保湿剂2次/d。疗程4周,进行皮损症状和体征评分。结果各症状评分均值由高向低排序为DCBA(P0.005)。A、B、C、D 4组间的有效率分别为46.34%,55.81%,77.27%和91.49%(P0.005)。结论马齿苋冷湿敷配合吡美莫司乳膏外涂,加用抗组胺药物可以明显提高本病的治愈率。     

外用1%吡美莫司乳膏治疗白癜风临床疗效观察

【摘要】：目的：观察局部外用1%吡美莫司乳膏治疗白癜风的临床疗效及安全性。方法：给予49例白癜风患者1%吡美莫司乳膏,每日2次外用,每两个月随访一次,观察治疗后靶皮损复色情况。结果：49例患者共计53处皮损,外用1%吡美莫司乳膏4-6个月后,22例达到不同程度的复色,有效率为55.10％,显效率为22.45%。除了2例患者用药后出现面部痤疮,其它无任何不良反应。结论：局部外用1%吡美莫司乳膏治疗白癜风疗效较好,不良反应少。     

吡美莫司联合中药当归饮子加减治疗面部激素依赖性皮炎疗效观察

目的观察1%吡美莫司联合中药当归饮子加减治疗面部激素依赖性皮炎的疗效和安全性。方法80例患者随机分为两组,治疗组41例,予1%吡美莫司乳膏外涂,口服中药当归饮子,均2次/d;对照组39例,予咪唑斯汀10mg 1次/d口服,外涂复硅霜。两组均30天为一疗程,连用2个疗程。结果治疗组有效率为87.80%,对照组为28.21%,两者比较差异有显著性(P<0.005)。以红斑、脱屑、丘疹为主要表现的患者反应良好,以毛细血管扩张和皮肤萎缩为主要表现的反应较差;红斑、脱屑、丘疹治疗后皮损积分下降明显(P<0.01);6例(14.6%)患者出现局部刺激反应,均在治疗后第1天。结论1%吡美莫司联合中药当归饮子加减对面部激素依赖性皮炎疗效好,无不良反应。     

NB-UVB联合百癣夏塔热片治疗寻常型银屑病疗效观察

目的:观察NB-UVB联合百癣夏塔热片治疗寻常型银屑病的疗效及不良反应。方法:采用随机对照临床试验,将81例符合纳入标准的患者随机分为两组,治疗组45例,对照组36例。治疗组采用NB-UVB光疗,同时口服百癣夏塔热片,对照组单独采用NB-UVB光疗。结果:治疗组有效率为80.0%,对照组有效率为50.3%,治疗组有效率高于对照组,差异具有统计学意义(P<0.05)。结论:NB-UVB联合百癣夏塔热片治疗寻常型银屑病疗效明显,且不良反应小,安全性高,值得临床推广。     

丙酸氟替卡松联合复方多黏菌素B治疗湿疹临床观察

目的观察丙酸氟替卡松乳膏联合复方多黏菌素B软膏治疗湿疹的临床疗效及安全性。方法将入选的120例湿疹患者随机分为两组,治疗组60例,1次/d丙酸氟替卡松乳膏,2次/d使用复方多黏菌素B软膏涂于皮疹处。对照组60例,单用丙酸氟替卡松乳膏,1次/d,疗程14天。结果治疗组第7天和第14天时有效率分别为51.67%为78.33%;对照组分别为41.67%和58.33%。仅治疗第14天时差异有统计学意义(P0.01)。治疗过程中均未出现严重的不良反应。结论丙酸氟替卡松乳膏联合复方多黏菌素B软膏治疗湿疹效果较好,且无明显不良反应。     

蜈黛软膏治疗慢性湿疹疗效观察

目的探讨蜈黛软膏治疗慢性湿疹的临床疗效。方法将64例慢性湿疹患者分为治疗组36例,外用蜈黛软膏治疗,2次/d;对照组28例,外用糠酸莫米松治疗,2次/d。均治疗3周后进行疗效判定。结果治疗组和对照组有效率分别为69.44%和71.43%,两组比较差异无统计学意义(P>0.05)。结论蜈黛软膏治疗慢性湿疹安全有效,且无明显不良反应。     

复方丙酸氯倍他索软膏联合5%水杨酸软膏外用治疗慢性湿疹疗效观察

目的评价复方丙酸氯倍他索软膏联合5%水杨酸软膏治疗慢性湿疹的临床疗效及安全性。方法选择我院门诊2012年1月—2013年6月收治的134例慢性湿疹患者,按照患者自愿的原则,将患者分为试验组(74例),对照组1(30例)和对照组2(30例)。对照组1单独给予复方丙酸氯倍他索软膏外用,对照组2单独给予5%水杨酸软膏外用,试验组采用两种药物联合外用,分别于治疗后2周、4周、6周观察疗效,并进行统计学分析。结果治疗2周、4周、6周时,试验组有效率均优于两个对照组,而两个对照组中对照组1的疗效也优于对照组2,差异均具有统计学意义(P0.05)。结论复方丙酸氯倍他索软膏联合5%水杨酸软膏外用治疗慢性湿疹临床疗效显著,疗程短,患者依从性好。     

NB-UVB联合复方氟米松治疗掌跖角化性湿疹疗效观察

目的 观察窄谱中波紫外线(NB-UVB)联合复方氟米松软膏治疗掌跖角化性湿疹的疗效。方法 60例皮肤科门诊掌跖角化性湿疹患者随机分为两组,治疗组30例采用联合治疗方法,即隔日1次NB-UVB照射,初始剂量通常为最小红斑量(MED)的70%或者(0.3～0.5)J/cm2,复方氟米松软膏外用,2次/d;对照组30例仅外用复方氟米松软膏治疗,2次/d。3周后观察疗效。结果 治疗组有效率为96.67%,对照组为76.67%,两组差异有统计学意义(P<0.05)。结论 NB-UVB联合复方氟米松软膏治疗掌跖角化性湿疹疗效较好。     

Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial

BACKGROUND: Staphylococcus aureus has a peculiar ability to colonize the skin of patients with eczema and atopic dermatitis (AD), and is consistently found in eczematous skin lesions in these patients. A correlation between the severity of the eczema and colonization with S. aureus has been demonstrated, and it has been determined that bacterial colonization is an important factor aggravating skin lesions. Patients colonized with S. aureus have been treated with antibiotics in several open and double-blind placebo-controlled studies, with conflicting results. OBJECTIVES: To investigate the colonizing features of S. aureus in the lesional and nonlesional skin of patients with eczema and AD in China and to compare the therapeutic effect of mupirocin plus hydrocortisone butyrate with vehicle ointment plus hydrocortisone butyrate. METHODS: A multicentre, double-blind randomized trial was conducted. Eczema Area and Severity Index (EASI) scores were evaluated before the start of the trial and on the 7th, 14th and 28th day of treatment. Swabs for bacterial isolation were taken from lesional skin before the start of the trial and on the 7th, 14th and 28th day of treatment, and from nonlesional skin only before the start of the trial. A combination topical therapy with mupirocin plus hydrocortisone butyrate ointment was used in the experimental group, with vehicle ointment plus hydrocortisone butyrate ointment as a control. RESULTS: Of 327 patients enrolled in the study, 208 had eczema and 119 had AD. Bacteria were isolated from 70.2% of lesional and 32.7% of nonlesional skin samples from patients with eczema, of which S. aureus accounted for 47.3% and 27.9%, respectively. Bacteria were isolated from 74.8% of lesional and 34.5% of nonlesional skin samples from patients with AD, of which S. aureus accounted for 79.8% and 80.5%, respectively. The colonization density of S. aureus was markedly higher in lesional than in nonlesional skin, both in patients with eczema and with AD (P < 0.01, P < 0.05), and was positively correlated with lesion severity. Considering the EASI scores before and after treatment and the final effective rate, good therapeutic effects were obtained in both the combination experimental groups and the control groups (P < 0.01), and there were no differences in the global therapeutic effect between the two groups in patients with eczema and with AD (P > 0.05). However, in patients with eczema with a clinical score of > 8 or in patients with AD with a clinical score of > 7, the therapeutic effect in the experimental groups was superior to that in the control groups (P < 0.05) on the 7th day of treatment. There were no differences between the two groups on the 14th and 28th days of treatment (P > 0.05). Following the improvement of symptoms and signs of eczema and AD, the positive rates of bacteria and S. aureus were reduced on the 7th day of treatment. CONCLUSIONS: This study confirmed that lesional skin of patients with eczema and AD was more frequently colonized with S. aureus than was nonlesional skin. The more severe the eczema, the higher the colonization rate of S. aureus, and S. aureus was also more often present in lesional and nonlesional skin in patients with AD than in those with eczema. Staphylococcus aureus infection is related to the pathogenesis of eczema and AD. An antibiotic-corticosteroid combination and corticosteroid alone both gave good therapeutic effect in eczema and in AD, and both reduced colonization by S. aureus. Early combined topical therapy is beneficial to patients with moderate to severe eczema and AD, and it is unnecessary to use antibiotics at later stages of disease or in mild eczema or AD.     

308nm准分子激光联合吡美莫司软膏治疗白癜风临床观察

目的评价308nm准分子激光联合吡美莫司软膏治疗白癜风的疗效和安全性。方法将150例白癜风患者随机分成3组。治疗组50例,308nm准分子激光(2次/周)联合吡美莫司软膏(2次/d)治疗,疗程12周。对照1组50例,单纯予308nm准分子激光治疗,用法同上。对照2组50例,单纯予吡美莫司软膏治疗,用法同上。结果治疗组有效率88.00%,对照1组为70.00%,对照2组为42.00%。治疗组和对照1组及对照2组比较,有效率差异有统计学意义(P<0.05)。治疗组皮损位于面颈部、躯干和四肢者疗效优于对照组(P<0.05),3组肢端皮损疗效差异无统计学意义(P>0.05)。患者均未出现严重不良反应。结论 308nm准分子激光联合吡美莫司软膏治疗位于面颈部、躯干和四肢的白癜风起效快,疗效好,不良反应少。     

润燥止痒胶囊联合咪唑斯汀缓释片治疗慢性湿疹疗效观察

目的观察润燥止痒胶囊联合咪唑斯汀治疗慢性湿疹的临床疗效。方法将80例临床确诊的慢性湿疹患者随机分为两组,治疗组40例口服润燥止痒胶囊4粒,3次/d,同时口服咪唑斯汀缓释片10mg,外用复方薄荷脑软膏,2次/d;对照组40例口服咪唑斯汀缓释片10mg,外用复方薄荷脑软膏,2次/d;连续治疗4周,根据评分标准进行疗效比较。结果治疗组有效率为87.5%,对照组为67.5%。两组有效率差异有显著性(P<0.05)。结论润燥止痒胶囊联合咪唑斯汀可有效治疗慢性湿疹。     

百癣夏塔热片联合窄波UVB治疗寻常型银屑病疗效评价

目的:评价百癣夏塔热片联合窄波UVB治疗寻常型银屑病的疗效。方法:87例患者随机分为2组,治疗组(42例)采用百癣夏塔热片联合窄波UVB治疗,对照组(45例)仅窄波UVB照射,两组均外擦醋酸曲安尿素软膏,疗程均为8周。结果:两组有效率分别为92.9%和77.8%,差异有显著性(P0.05)。结论:百癣夏塔热片联合窄波UVB治疗寻常型银屑病有效。     

复方氟米松软膏与丙酸氯倍他索乳膏治疗慢性湿疹和神经性皮炎疗效对比研究

[摘要] 目的 观察奥深治疗慢性湿疹和神经性皮炎的临床疗效和不良反应。方法 151例慢性湿疹和神经性皮炎患者随机分为奥深治疗组76例（其中慢性湿疹45例，神经性皮炎31例），丙酸氯倍他索乳膏对照组75例（其中慢性湿疹43例，神经性皮炎32例），分别观察治疗后1、2、3周的临床疗效和不良反应。结果 治疗组和对照组治疗1周后的临床痊愈率分别为13.16 %和6.67%，两组比较无统计学差异（P>0.05），治疗组治疗后2、3周的临床痊愈率分别为53.95%和63.16%，对照组治疗后2、3周的临床痊愈率分别为28.00%和37.33 %，两组比较差异有统计学意义（P<0.05）；治疗组治疗后1、2、3周的临床有效率分别为43.42%，84.21%和92.11%，对照组治疗后1、2、3周的临床有效率分别为18.67 %，60.00%和69.33%，两组临床有效率比较差异均有统计学意义（P<0.05）。且未见有明显临床意义的不良反应。结论 奥深治疗慢性湿疹和神经性皮炎的疗效优于丙酸氯倍他索乳膏，无明显的不良反应，是治疗慢性湿疹和神经性皮炎较为理想药物。